Patients with lung cancer harboring drug-sensitive mutations on the EGFR gene, such as exon 19 deletion or exon 21 L858R mutations, show dramatic and durable responses to EGFR-TKIs [3]. The gene discussed is EGFR; the disease is lung carcinoma.